Liraglutide Lowers Palmitoleate Levels in Type 2 Diabetes. A Post Hoc Analysis of the LIRAFLAME Randomized Placebo-Controlled Trial

BACKGROUND: Liraglutide is a glucose-lowering medication used to treat type 2 diabetes and obesity. It is a GLP-1 receptor agonist with downstream metabolic changes beyond the incretin system, such as reducing the risk of cardiovascular complications. The understanding of these changes is critical f...

Descripción completa

Detalles Bibliográficos
Autores principales: Wretlind, Asger, Zobel, Emilie Hein, de Zawadzki, Andressa, Ripa, Rasmus Sejersten, Curovic, Viktor Rotbain, von Scholten, Bernt Johan, Mattila, Ismo Matias, Hansen, Tine Willum, Kjær, Andreas, Vestergaard, Henrik, Rossing, Peter, Legido-Quigley, Cristina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Clinical Diabetes and Healthcare
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10012104/
https://www.ncbi.nlm.nih.gov/pubmed/36992761
http://dx.doi.org/10.3389/fcdhc.2022.856485

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10012104/
https://www.ncbi.nlm.nih.gov/pubmed/36992761
http://dx.doi.org/10.3389/fcdhc.2022.856485

Ejemplares similares